We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+24.15%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$185M
Cap. Flow
+$75.5M
Cap. Flow %
5.81%
Top 10 Hldgs %
78.61%
Holding
39
New
8
Increased
5
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
TARS icon
Tarsus Pharmaceuticals
TARS
+$54.6M
2
STRO icon
Sutro Biopharma
STRO
+$16.6M
3
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
+$15.7M
4
EPZM
Epizyme, Inc
EPZM
+$9.02M
5
MTEM
Molecular Templates, Inc.
MTEM
+$8.29M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$34.4M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$13.1M
3
CDTX
Cidara Therapeutics
CDTX
+$3.74M
4
VTVT icon
vTv Therapeutics
VTVT
+$1.88M
5
NERV icon
Minerva Neurosciences
NERV
+$1.54M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
26
DELISTED
Molecular Templates, Inc.
MTEM
$7.91M 0.61%
+56,127
New +$8.29M
SRRK icon
27
Scholar Rock
SRRK
$7.22B
$7.45M 0.57%
+153,500
New +$5.57M
ALNA
28
DELISTED
Allena Pharmaceuticals
ALNA
$4.26M 0.33%
3,330,373
– –
BLU
29
DELISTED
BELLUS Health Inc.
BLU
$3.9M 0.3%
1,296,743
– –
SRRA
30
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.25M 0.25%
202,803
– –
GRTX
31
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.46M 0.19%
+241,000
New +$2.64M
SPRY icon
32
ARS Pharmaceuticals
SPRY
$600M
$1.66M 0.13%
+35,750
New +$1.19M
ITRM
33
DELISTED
Iterum Therapeutics
ITRM
$1.52M 0.12%
102,554
– –
NBRV
34
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.03M 0.08%
17,026
– –
NERV icon
35
Minerva Neurosciences
NERV
$245M
$144K 0.01%
7,693
-61,057
-89% -$1.54M
CDTX
36
DELISTED
Cidara Therapeutics
CDTX
– –
-65,613
Closed -$3.74M
VTVT icon
37
vTv Therapeutics
VTVT
$130M
– –
-26,550
Closed -$1.88M
BLCM
38
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-105,144
Closed -$691K
ETTX
39
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
– –
-199,953
Closed -$408K
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q4 2020 Portfolio in Review

As of Q4 2020, Frazier Management held 39 positions worth $1.3B, up 17% from $1.11B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Frazier Management deployed $75.5M of net new capital in Q4 2020, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Tarsus Pharmaceuticals: 1,917,157 shares worth $79.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AnaptysBio, an estimated $34.4M trimmed.

  • Frazier Management's largest Q4 2020 buy was Tarsus Pharmaceuticals: 1,917,157 shares worth $79.2M.
  • Frazier Management added most to Regenxbio in Q4 2020, an estimated $5.86M increase.
  • Frazier Management's biggest Q4 2020 reduction was AnaptysBio, cutting an estimated $34.4M.
  • Frazier Management fully exited Cidara Therapeutics in Q4 2020, selling an estimated $3.74M.
  • Frazier Management's ten largest holdings make up 79% of its $1.3B portfolio in Q4 2020.
  • Frazier Management opened 8 new positions and closed 4 in Q4 2020.
  • Frazier Management's portfolio value rose 17% quarter-over-quarter to $1.3B.

Based on Frazier Management's 13F filing for Q4 2020, filed 11 Feb 2021.